Have you been paying attention to shares of Brainsway Ltd. Sponsored ADR (BWAY) ? Shares have been on the move with the stock up 21.1% over the past month. The stock hit a new 52-week high of $8.28 in the previous session. Brainsway Ltd. Sponsored ADR has gained 21.5% since the start of the year compared to the 9.5% move for the Zacks Medical sector and the 8.4% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surpri ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the s ...

PM Images/DigitalVision via Getty Images BrainsWay (NASDAQ:BWAY) (OTCPK:BRSYF) reported strong earnings again in the second quarter, particularly from a margin perspective. This strength is particularly notable given Neuronetics (STIM) recent struggles. BrainsWay's revenue was up 28% YoY, and while growth is moderating, this is coming against increasingly difficult comparable periods. I previously suggested that BrainsWay's stock should continue to rerate higher as the company's profitable growth trajectory ...

Investors might want to bet on Brainsway Ltd. Sponsored ADR (BWAY) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earni ...

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $6.82, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $11.75 indicates a 72.3% upside potential. The average comprises four short-term price targets ranging from a low of $9 to a high of $15, with a standard deviation of $2.50. While the lowest estimate indicates an increase of 32% from the curren ...

BrainsWay Ltd. (NASDAQ:BWAY) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Steve Lichtman - Oppenheimer Jeffery S. Cohen - Ladenburg Thalmann & Company Operator Good day and welcome to the BrainsWay Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask ...

Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth Consecutive Quarter Raising Lower End of Full-Year 2024 Revenue Guidance to Range of $38.5 Million to $40 Million Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global lead ...

Brainsway Ltd. Sponsored ADR (BWAY) shares rallied 9.3% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.6% gain over the past four weeks. Shares of Brainsway has been rising for the past three months on the back of its solid first-quarter performance. The recent price rise is likely due to positive sentiments of investors that is likely to continue as the compa ...

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the re ...

BrainsWay Ltd. (BWAY) recently signed an exclusive multi-year distribution agreement with a specialty distributor serving both the acute hospital and non-acute healthcare spaces in Canada. The deal will enable the company to make a broad market entry into Canada for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) system. Per management, a significant mental health crisis is prevalent in Canada, with the current existence of a substantial barrier to treatment. One in two Canadians have, or ...